2023 World Conference on Lung Cancer (Posters)-EP01.01. Impact of Smoking on Survival in NSCLC Patients Treated with Chemoimmunoimmunotherapy or Chemotherapy: A Real-world Data Study

EP01.01. Impact of Smoking on Survival in NSCLC Patients Treated with Chemoimmunoimmunotherapy or Chemotherapy: A Real-world Data Study - PDF(Slides)

Back to course

Pdf Summary

A study conducted by Ayah Bani Mostafa from the Jordan University of Science and Technology aimed to evaluate the impact of smoking on the survival of non-small cell lung cancer (NSCLC) patients treated with either chemotherapy or chemoimmunoimmunotherapy drugs. The study used real-world data from the AACR Project GENIE BPC NSCLC v2.0 dataset and included 536 patients diagnosed with stage I-III NSCLC.<br /><br />The study found that smoking status did not have a significant effect on overall survival in NSCLC patients undergoing treatment with chemotherapy or chemoimmunotherapy. The median overall survival for smokers and non-smokers was similar in both treatment groups.<br /><br />The study also analyzed other patient characteristics such as age, sex, histology, and stage. No significant differences were observed in these characteristics between patients receiving chemotherapy or chemoimmunotherapy.<br /><br />The results of the study suggest that smoking status may not be a major determinant of survival in NSCLC patients undergoing treatment. However, further research is needed to confirm these findings and explore other factors that may influence survival outcomes in NSCLC patients.<br /><br />The author acknowledges the contributions of Ashaar Al-Akhras, Shaden Tashtoush, and Shadi Hamouri, MD, MRCSI, FCCP, FEBTS, FACS in this work.

Asset Subtitle

Ayah Bani Mostafa

Meta Tag

Speaker Ayah Bani Mostafa

Topic Risk Factors, Risk Reduction & Tobacco Control

Keywords

study

smoking

impact

survival

non-small cell lung cancer

NSCLC

chemotherapy

chemoimmunotherapy

real-world data

patient characteristics